Comparison of Calcium EDTA and succimer in treating patients being intoxicated with lead by taking oral opium

Comparison of treatment response to Calcium EDTA and succimer in patients being intoxicated with lead by taking oral opium

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180131038581N1

Enrollment

Registered

2018-06-19

Start date

2018-10-07

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lead toxicity. Toxic effects of lead and its compounds

Interventions

Intervention 1: Intervention group 1: Patients in this group receive Calcium EDTA plus Succimer placebo. Intervention 2: Intervention group 2: Patients in this group receive Succimer plus Calcium EDTA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The presence of intoxication symptoms Oral ingestion of opium Laboratory confirmation of lead poisoning

Exclusion criteria

Exclusion criteria: Dissatisfaction to participate in the study Presence of other causes for patient symptoms Contact with a substance other than opium

Design outcomes

Primary

Measure	Time frame
Lead level. Timepoint: Before treatment, 5 days after treatment, and 2 weeks after treatment. Method of measurement: Clinical symptoms and blood test.	—

Secondary

Measure	Time frame
Abdominal pain. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Questionnaire.;Constipation. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Questionnaire.;Systolic blood pressure. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Sphygmomanometer.;Creatinine clearance. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.;Hemoglobin level. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.;Levels of liver enzymes. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.	—

Measure

Time frame

Abdominal pain. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Questionnaire.;Constipation. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Questionnaire.;Systolic blood pressure. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Sphygmomanometer.;Diastolic blood pressure. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Sphygmomanometer.;Creatinine clearance. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.;Hemoglobin level. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.;Levels of liver enzymes. Timepoint: Before treatment, 5 days after treatment and 2 weeks after treatment. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamid Mousavi

Bandare-abbas University of Medical Sciences

h.mousavi@hums.ac.ir+98 76 3333 3280

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026